Navigation Links
Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
Date:12/11/2009

SAN DIEGO, Dec. 11 /PRNewswire/ -- Ambit Biosciences Corporation announced today the enrollment and dosing at the University of Texas M. D. Anderson Cancer Center of the first patient in the ACE (AC220 Monotherapy Efficacy) Phase 2 pivotal trial in patients with relapsed or refractory acute myeloid leukemia (AML). AC220 is a novel, orally available, potent and highly selective small molecule that was specifically designed as a FMS-like tyrosine kinase-3 (FLT3) inhibitor. The ACE study is designed to be a pivotal trial that could potentially support a United States regulatory filing for AC220 to address a targeted AML patient population with the internal tandem duplication (ITD) activating mutation for FLT3.

"Based on the promising results of our first-in-human clinical trial presented at the American Society of Hematology (ASH), we are pleased to advance AC220 into this important Phase 2 study in AML. We are deeply grateful to our investigators, their staff, and their patients, as well as our entire team at Ambit, for their vital contributions in achieving this significant milestone," said Wendell Wierenga, EVP of Research and Development at Ambit. "If the ACE study is successful, AC220 could emerge as the first once-a-day, orally available targeted therapy for AML patients. Over the next several months we plan to initiate additional clinical trials with AC220 to support the potential registration in AML, and to explore its utility in certain types of solid tumors."

"AML is a devastating disease for which few treatment options exist," said Jorge Cortes MD, Internist and Professor, Deputy Chair, Department of Leukemia, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, and principal investigator for the ACE Study. "There are no treatments currently approved by the FDA that specifically target the activating ITD mutations of the FLT3 kinase, present in 2
'/>"/>

SOURCE Ambit Biosciences Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT
2. YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES
3. Cell Biosciences Acquires Protein Forest
4. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
5. Dow AgroSciences, Agrisoma Biosciences Announce Research and Commercial License Option Agreement for Agricultural Crops
6. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
7. YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA
8. American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor
9. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
10. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING
11. Regado Biosciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Texas , Dec. 24, 2014  Vermillion, ... focused on gynecologic disease, announced today that the ... investors including Oracle Investment Management, Jack W. ... directors. Total proceeds were $10.5 million, before offering ... capital and general corporate purposes. Under ...
(Date:12/24/2014)... 2014 GMO corn cases filed across ... are in the process of being consolidated in a ... is In Re: Syngenta AG MIR 162 Corn Litigation, ... the District of Kansas. , Management of the Syngenta ... to U.S. District Judge John W. Lungstrum.* , As ...
(Date:12/24/2014)... On Friday, December 19, 2014, President ... and Continuing Resolution Appropriations Act of 2015, which ... eligible to receive funding through the Congressionally Directed ... of Defense (DoD). The Hydrocephalus Association (HA), working ... is celebrating this victory for the over 1 ...
(Date:12/24/2014)... Nashville, Tenn. (PRWEB) December 23, 2014 ... Hill was elected treasurer for the American Society ... to advancing knowledge and research in reproductive medicine. ... fills a seat on the executive board and will ... , Dr. Hill has actively supported ASRM since ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3
... ... easier, or less smelly, thanks to a new indoor composting kit from SCD Probiotics. ... scraps in an airtight bucket. Bokashi, made using SCD,s probiotic technology, helps accelerate the ... ...
... AM EST (Webcast begins at 8:30 AM, Where: Kimmel ... launches its first full day with the announcement of the ... address by Harold Varmus, co-chair of President Obama,s Council of ... simulcast of the announcement of the laureates by the Norwegian ...
... May 17 Sigma-Aldrich Corporation (Nasdaq: SIAL ) will be presenting ... at 1:15 PM CDT ( 2:15 PM EDT ) in ... Internet available at http://investor.sigmaaldrich.com/ .  Users can click the "Webcast" icon to ... , ...
Cached Biology Technology:All Seasons Indoor Composter™ and All Seasons Bokashi™ Provide Easy Way to Recycle Food Waste Right in Your Kitchen 2All Seasons Indoor Composter™ and All Seasons Bokashi™ Provide Easy Way to Recycle Food Waste Right in Your Kitchen 3Sigma-Aldrich Corporation to Present at the Baird's 2010 Growth Stock Conference on Thursday, May 20, 2010 2
(Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... addition of the "Samsung Galaxy S5 - ... report to their offering. ... totally different sensing technology than the iPhone 5S, ... sensor in its product. The Galaxy ...
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ... "Global Chemical Sensor Market 2015-2019" report to ... One major trend upcoming in ... sensors in biomedical applications. Chemical sensors help in ... diagnosis during surgical procedures. The Global Chemical Sensor ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... ) live high up in the rainforest canopy. When ... the behaviour of the ants is dramatically changed. They ... fungus into dying at a spot that provides optimal ... Central,s open access journal BMC Ecology , looks ...
... the past decades, researchers seeking to understand molecular mechanisms ... DNA microarrays to interrogate tissues specimen of patients for ... Jointly, such gene expression status of each gene ... transcripts, constitutes the gene expression profile. Since each of ...
... Edmonton Researchers with the Faculty of Medicine & ... some "protective" T-cells can kill neurons. This finding is ... being touted in the medical community as a potential ... Fabrizio Giuliani and his post-doctoral fellow, Yohannes Haile, both ...
Cached Biology News:Zombie ants have fungus on the brain 2Medusa-structure of gene regulatory network: Dominance of transcription factors in cancer subtypes 2Medusa-structure of gene regulatory network: Dominance of transcription factors in cancer subtypes 3Medusa-structure of gene regulatory network: Dominance of transcription factors in cancer subtypes 4Discovery demonstrates potential MS therapy could kill brain cells 2
MAb to HLA, Class II-DR+DP Dry Ice: No Preservative: NaN3 Availability When Not in Inventory: 14-21 Business Days...
... surface is produced by a patented microwave ... giving more consistent, even cell attachment, increased ... attachment and growth uunder difficult conditions, including ... may provide a more ecominic alternative to ...
... array system, 100-240 V, uses multiplex suspension ... analysis of up to 100 proteins and ... suspension array is composed of up to ... may be conjugated with a unique reactant ...
... PYREX Delong style shaker flasks have three ... agitation of solutions to improve oxygen or ... reciprocating shakers. The long neck reduces splashing ... Their uniform wall thickness provides the proper ...
Biology Products: